Immunological Quantitation of Rabbit Plasminogen Activator Inhibitor-1 in Biological Samples

Thu-Hoa Ngo; Paul J. Declerck

doi:10.1055/s-0037-1614863

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1999; 82(05): 1510-1515
DOI: 10.1055/s-0037-1614863

Rapid Communications

Schattauer GmbH

Immunological Quantitation of Rabbit Plasminogen Activator Inhibitor-1 in Biological Samples

Evidence that Rabbit Platelets Do not Contain PAI-1

Authors

Thu-Hoa Ngo

¹From the Laboratory for Pharmaceutical Biology and Phytopharmacology, Faculty of Pharmaceutical Sciences, Katholieke Universiteit Leuven, Belgium
Paul J. Declerck

¹From the Laboratory for Pharmaceutical Biology and Phytopharmacology, Faculty of Pharmaceutical Sciences, Katholieke Universiteit Leuven, Belgium

Abstract

Summary

Two immunoassays for the specific quantitation of rabbit plasminogen activator inhibitor-1 (PAI-1) antigen and activity in biological samples were developed and applied for the evaluation of PAI-1 in rabbits. Levels of PAI-1 antigen in rabbit plasma were 9.8 ± 4.6 ng/ml (mean ± SD, n = 6), with a corresponding value of 20.5 ± 13.5 ng/ml for PAI-1 activity. In rabbit serum PAI-1 antigen was 11.8 ± 4.9 ng/ml (n = 6) and PAI-1 activity was 2.9 ± 2.0 ng/ml (n = 6). Endotoxin injection (20 μg/kg, iv) induced a time-dependent increase of both PAI-1 antigen and PAI-1 activity levels in rabbit plasma, eventually resulting in a 40- to 90-fold increase (p <0.0001 vs baseline). A linear correlation was found between PAI-1 antigen and activity levels in normal plasma (r = 0.90, n = 6, p <0.05) and in plasma from endotoxin-treated rabbits (r = 0.98, n = 20, p <0.001). Analysis of PAI-1 antigen and activity in lysates of washed rabbit platelets revealed the absence of PAI-1 (i.e. <0.03 ng/10⁸ platelets).

In conclusion, development of specific immunological assays allowed the quantitation of PAI-1 in rabbit samples. In striking contrast to other species (human, rat, mouse, pig) rabbit platelets lack detectable amounts of PAI-1 (i.e. >100-1000 fold lower vs other species studied). This observation may have important implications for the use of experimental rabbit models especially in studies on the role of platelets in various pathological conditions including thrombosis and atherosclerosis.

Key words

Thrombosis - fibrinolysis - serpin - atherosclerosis - platelets

Full Text

References

References
1 Kruithof EKO, Tran-Thang C, Ransijn A, Bachmann F. Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. Blood 1984; 64: 907-13.
2 Declerck PJ, Juhan-Vague I, Felez J, Wiman B. Pathophysiology of fibrinolysis. J Int Med 1994; 236: 425-32.
3 Van Meijer M, Pannekoek H. Structure of plasminogen activator inhibitor 1 (PAI-1) and its function in fibrinolysis: an update. Fibrinolysis 1995; 9: 263-76.
4 Diéval J, Nguyen G, Gross S, Delobel J, Kruithof EKO. A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor type-1. Blood 1991; 77: 528-32.
5 Lee MH, Vosburgh E, Anderson K, McDonagh J. Deficiency of plasma plasminogen activator inhibitor 1 results in hyperfibrinolytic bleeding. Blood 1993; 81: 2357-62.
6 Schleef RR, Higgins DL, Pillemer E, Levitt L.J. Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor. J Clin Invest 1989; 83: 1747-52.
7 Fay WP., Shapiro AD, Shih JL, Schleef RR, Ginsburg D. Complete deficiency of plasminogen activator inhibitor type 1 due to a frame-shift mutation. N Engl J Med 1992; 327: 1729-33.
8 Declerck PJ, Alessi MC, Verstreken M, Kruithof EKO, Juhan-Vague I, Collen D. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 1988; 71: 220-5.
9 Declerck PJ, Verstreken M, Collen D. An immunofunctional assay for active plasminogen activator inhibitor-1 (PAI-1). Fibrinolysis 1988; 2: 77-8.
10 Declerck PJ, Verstreken M, Collen D. Immunoassay of murine t-PA, u-PA and PAI-1 using monoclonal antibodies raised in gene-inactivated mice. Thromb Haemost 1995; 74: 1305-9.
11 Ngo TH, Verheyen S, Knockaert I, Declerck PJ. Monoclonal antibody-based immunoassays for the specific quantitation of rat PAI-1 antigen and activity in biological samples. Thromb Haemost 1998; 79: 808-12.
12 Collen D, Stassen JM, Verstraete M. Thrombolysis with human entrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus, and route of administration. J Clin Invest 1983; 71: 368-76.
13 Jang IK, Gold HK, Ziskind AA, Fallon JT, Holt RE, Leinbach RC, May JM, Collen D. Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. A possible explanation for resistance to coronary thrombolysis. Circulation 1989; 79: 920-8.
14 Jang IK, Gold HK, Ziskind AA, Leinbach RC, Fallon JT, Collen D. Prevention of plateletrich arterial thrombosis by selective thrombin inhibition. Circulation 1990; 81: 219-25.
15 Hofmann KJ, Mayer EJ, Schultz LD, Socher SH, Reilly CF. Purification and characterisation of recombinant rabbit plasminogen activator inhibitor-1 expressed in Saccharomyces cerevisiae. Fibrinolysis 1992; 6: 263-72.
16 Ngo TH, Bijnens AP, Knockaert I, Declerck PJ. Expression, purification and characterization of recombinant rat plasminogen activator inhibitor-1. Fibrinolysis 1997; 11: 37-43.
17 Verheijen JH, Chang GTG, Kluft C. Evidence for the occurrence of a fast-acting inhibitor for tissue-type plasminogen activator in human plasma. Thromb Haemost 1984; 51: 392-5.
18 Kruithof EKO, Nicolosa G, Bachmann F. Plasminogen activator inhibitor 1: Development of a radioimmunoassay and observations on its plasma concentration during venous occlusion and after platelet aggregation. Blood 1987; 70: 1645-53.
19 Booth NA, Simpson AJ, Croll A, Bennett B, MacGregor IR. Plasminogen activator inhibitor (PAI-1) in plasma and platelets. Br J Haematol 1988; 70: 327-33.
20 Wiman B, Lindahl T. Almquist $ Evidence for a discrete binding protein of plasminogen activator inhibitor in plasma. Thromb Haemost 1988; 59: 392-5.
21 Declerck PJ, De Mol M, Alessi MC, Baudner S, Paques EP, Preissner KT, Muller-Berghaus G, Collen D. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J Biol Chem 1988; 263: 15454-61.
22 Bijnens AP, Knockaert I, Cousin E, Kruithof EKO, Declerck PJ. Expression and characterization of recombinant porcine plasminogen activator inhibitor-1. Thromb Haemost 1997; 77: 350-6.
23 Colucci M., Paramo JA, Collen D. Generation in plasma a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation. J Clin Invest 1985; 75: 818-24.
24 Levi M, Biemond BJ, van Zonneveld AJ, ten Cate JW, Pannekoek H. Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis. Circulation 1992; 85: 305-12.
25 Biemond BJ, Levi M, Coronel R, Janse MJ, ten Cate JW, Pannekoek H. Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Effects of a plasminogen activator inhibitor type 1-Neutralizing monoclonal antibody. Circulation 1995; 91: 1175-81.
26 Hekman CM, Loskutoff DJ. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J Biol Chem 1985; 260: 11581-7.
27 Lang IM, Marsh JJ, Konopka RG, Olman MA, Binder BR, Moser KM, Schleef RR. Factors contributing to increased vascular fibrinolytic activity in mongrel dogs. Circulation 1993; 87: 1990-2000.
28 Konkle BA, Schick PK, He X, Liu RJ, Mazur EM. Plasminogen activator inhibitor -1 mRNA is expressed in platelets and megakaryocytes and the megakaryoblastic cell line CHRF-288. Arterioscler Thromb 1993; 13 (05) 669-74.
29 Alessi MC, Chomiki N, Berthier R, Schweitzer A, Fossat C, Juhan-Vague I. Detection of plasminogen activator inhibitor-1 (PAI-1) mRNA in human megakaryocytes by in situ hybridization. Thomb Haemost 1994; 72 (06) 931-6.